Market Research Report
Osteoporosis - Pipeline Review, H1 2020
|Published by||Global Markets Direct||Product code||232788|
|Published||Content info||353 Pages
Delivery time: 1-2 business days
|Osteoporosis - Pipeline Review, H1 2020|
|Published: April 30, 2020||Content info: 353 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H1 2020, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.
Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 1, 8, 7, 22, 4, 63, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 13 and 13 molecules, respectively.
Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.